Ophthalmology
Aflibercept 8 mg: Long-Term Outcomes in PULSAR
Korobelnik JF, Lanzetta P, Leal S, et al; PULSAR investigators
The Phase 3 PULSAR trial evaluated intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration. At 96 weeks, extended dosing intervals of up to 16 weeks maintained visual and anatomical outcomes comparable to the standard 2 mg every-8-weeks regimen. These results support the use of high-dose aflibercept to reduce treatment burden while preserving efficacy.
Previous Article
- • Deep Learning-Assisted Analysis of Biomarker Changes in Therapy-Resistant Neovascular Age-Related Macular Degeneration
- • Real-World Safety and Efficacy of 8 mg Aflibercept in nAMD
- • Case Report: Aflibercept for DME in Vitrectomized Eyes
- • Guideline Recommendations for Optimal Anti-VEGF Therapy in AMD
- • AI-Assisted Fluid Volume Analysis of Treatment-Naive nAMD in the Real World
- • Consecutive Monthly Loading Administrations of Aflibercept 8 Mg for Treatment-Naïve Exudative AMD
- • Outcomes of High-Dose Aflibercept in Exudative nAMD
- • PULSAR: Intravitreal Aflibercept 8 mg in nAMD
- • PHOTON: Intravitreal Aflibercept 8 mg in Diabetic Macular Edema
- • CANDELA: Aflibercept 8 mg in Patients With nAMD
- • Aflibercept 8 mg: Long-Term Outcomes in PULSAR
- • Plain Language Summary of Publication of the 48-Week Results From PULSAR
- • High-Dose Aflibercept for Refractory AMD
